Takeda reports data from Phase II narcolepsy type 1 therapy trial

Takeda has reported findings from the Phase II clinical trial of TAK-994 for treating patients with narcolepsy type 1 (NT1).

Dubbed TAK-994-1501, the study evaluated the safety and efficacy of TAK-994, an orexin receptor 2 (OX2R) agonist, for NT1 patients aged 18 to 65 years old.